

**AB-BIOTICS**

AB-BIOTICS is a Spanish company founded in Barcelona in 2004, leading Biotechnology and whose activity is diversified into two business areas based on the research, development, protection and distribution of biotech own unique solutions, with a mission to improve the health and wellbeing of people.

**COMPANY PROFILE as at**

11/30/14

Price	1,92
Price as at 07/20/2010	2,53
Equity Market Value	18.424.650,24 €
Nº of Shares	9.596.172
Max/Min	3,50/1,33




Volume	Shares	Turnover	Capital Increases
2014	2.118.000	5.798.000 €	2014 0 €
2013	670.000	1.313.000 €	2013 1.123.738 €
2012	714.000	1.742.000 €	2012 8.625.726 €
2011	258.000	740.000 €	2011 1.431.820 €
2010	1.005.000	2.918.000 €	

Ticker	ABB	Perc. of Equity Market Value in MAB	1,07%
Sector	Biotech / Pharma	Price Performance since 07/20/2010	-24,11%


Price Performance per year (%)	2010	2011	2012	2013	2014
AB Biotics	26,482	-9,688	-27,336	7,143	-14,667
MAB Index	-37,679	-6,312	2,293	183,437	-0,865
IBEX Small Cap Index	-18,316	-25,102	-24,448	44,290	-9,212
IBEX 35 Index	-17,428	-13,113	-4,655	21,417	8,612

**MAJOR SHAREHOLDERS**


Miquel Àngel Bonachera Sierra	13,24%
Segi Audivert Brugué	13,24%
Luis Sánchez-Lafuente Mariol	9,30%
Minority shareholders	64,22%




**Sales Revenue**




**Ebitda**



**Net Income**



**Volume**



## AB-BIOTICS

AB-BIOTICS is a Spanish company founded in Barcelona in 2004, leading Biotechnology and whose activity is diversified into two business areas based on the research, development, protection and distribution of biotech own unique solutions, with a mission to improve the health and wellbeing of people.

### INCOME (Annual)

	2011	2012	2013	Variation
Sales Revenue	2.256.205,95 €	1.641.605,80 €	818.682,00 €	-50%
Ebitda	-433.327,26 €	-2.327.508,96 €	-1.517.860,00 €	35%
Ebitda Margin	n.a.	n.a.	n.a.	
Net Income	-491.203,86 €	-2.073.878,73 €	-1.812.918,00 €	13%
Net Margin	n.a.	n.a.	n.a.	

Performance Information	2011	2012	2013	*2014
ROE	N.A.	N.A.	N.A.	N.A.
ROA	N.A.	N.A.	N.A.	N.A.
Equity Market Value / Sales**	7,01	9,04	26,37	22,51
Equity Market Value / EBITDA	N.A.	N.A.	N.A.	N.A.
EPS	N.A.	N.A.	N.A.	N.A.
PER	N.A.	N.A.	N.A.	N.A.
Return Rate	N.A.	N.A.	N.A.	N.A.
Nº of Shares	5.470.446	7.068.907	9.596.172	9.596.172
Price as at 12-31	2,89	2,10	2,25	N.A.
Price				1,92





\*2014 data is price / last public Financial Statements.

\*\*Sales Revenue



### Projection Ratios on estimation results of the Company in February 2014

	2014E	2015E	2016E
Equity Market Value / Sales**	5,26	1,32	0,84
Equity Market Value / EBITDA	N.A.	5,44	2,58
EPS	N.A.	0,25 €	0,62
PER	N.A.	7,53	3,09



Debt Analysis	2011	2012	2013	2014E
Total debt/Ebitda	N.A.	N.A.	N.A.	6,70
Ebitda/Finance Costs	N.A.	N.A.	N.A.	22,06
Total debt/Equity	0,50	0,56	0,52	0,99